Compound: oxaprozin
SMILES: O=C(O)CCc1oc(-c2ccccc2)c(n1)-c3ccccc3
InChIKey: OFPXSFXSNFPTHF-UHFFFAOYSA-N
Synonyms: oxaprozin, 21256-18-8, Daypro, 3-(4,5-Diphenyloxazol-2-yl)propanoic acid, Alvo, Oxaprozine, Oxaprozinum, Deflam, Oxaprozina, 4,5-Diphenyl-2-oxazolepropionic acid, 4,5-Diphenyl-2-oxazolepropanoic acid, WY-21743, WY-21,743, 2-Oxazolepropanoic acid, 4,5-diphenyl-, Duraprox, WY 21743, COXANTO, NSC310839, NSC-310839, DTXSID1045118, MHJ80W9LRB, beta-(4,5-Diphenyloxazol-2-yl)propionic acid, 3-(diphenyl-1,3-oxazol-2-yl)propanoic acid, CHEBI:7822, DTXCID9025118, Apo Oxaprozin, Rhoxal oxaprozin, Oxaprozin (USAN:USP:INN:BAN:JAN), Oxaprozin [USAN:USP:INN:BAN:JAN], 4,5 Diphenyl 2 oxazolepropionic Acid, Wy 21,743, RefChem:56403, M01AE12, 244-296-1, 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid, Oxaprozine [INN-French], Oxaprozinum [INN-Latin], Oxaprozina [INN-Spanish], MFCD00215977, Oxaprozinum;Wy21743, 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid, NSC 310839, CHEMBL1071, Voir, 2-OXAZOLEPROPIONIC ACID, 4,5-DIPHENYL-, .beta.-(4,5-Diphenyloxazol-2-yl)propionic acid, Danoprox, Dayrun, CAS-21256-18-8, Actirin, Xopane, SMR000058286, Daypro (TN), SR-01000076053, oxaprosin, Durapro, Duraprost, Oxaprozi, Oxapro, Walix, Oxaprozin, solid, EINECS 244-296-1, NCI310839, Oxaprozin (Standard), 4, 5-Diphenyl-2-oxazolepropionic acid, BRN 1083168, OXAPROZIN [INN], OXAPROZIN [JAN], OXAPROZIN [MI], OXAPROZIN [HSDB], OXAPROZIN [USAN], 3-(4,5-Diphenyl-2-oxazolyl)propionic acid, Maybridge1_008800, Prestwick0_001060, Prestwick1_001060, Prestwick2_001060, Prestwick3_001060, Spectrum2_001696, Spectrum3_001078, Spectrum4_001231, UNII-MHJ80W9LRB, Lopac-O-9637, OXAPROZIN [VANDF], OXAPROZIN [MART.], O 9637, OXAPROZIN [USP-RS], OXAPROZIN [WHO-DD], SCHEMBL3286, NCIStruc1_000799, NCIStruc2_000787, BIDD:PXR0149, Lopac0_000944, Oprea1_509470, BSPBio_001020, BSPBio_002696, KBioGR_001722, MLS000759535, MLS001424072, BIDD:GT0438, SPECTRUM1505267, Oxaprozin - Bio-X trade mark, SPBio_001652, SPBio_002940, Oxaprozin (JP18/USP/INN), BPBio1_001122, GTPL7252, orb1310364, orb3025231, OXAPROZIN [ORANGE BOOK], HMS566H22, HSDB 7586, HY-B0808R, KBio3_001916, MSK7199, OXAPROZIN [USP MONOGRAPH], GLXC-23892, HMS1571C22, HMS1922P17, HMS2051L15, HMS2093O08, HMS2098C22, HMS3262N10, HMS3393L15, HMS3652H17, HMS3715C22, HMS3885L11, HMS5082D16, Pharmakon1600-01505267, Wy21743, HY-B0808, Tox21_110059, Tox21_500944, 2-Oxazolepropanoic acid,5-diphenyl-, 2-Oxazolepropionic acid,5-diphenyl-, BDBM50002861, CCG-36508, EBC-04209, MSK7199-100M, NCGC00014711, NSC758949, s4230, SBB053166, 4,5-diphenyloxazole-2-propanoic acid, AKOS000206807, Tox21_110059_1, CS-7975, DB00991, FO26614, KS-5196, LP00944, NC00214, NSC-758949, SDCCGSBI-0050918.P004, NCGC00014711-01, NCGC00014711-02, NCGC00014711-03, NCGC00014711-04, NCGC00014711-05, NCGC00014711-06, NCGC00014711-07, NCGC00014711-08, NCGC00014711-09, NCGC00014711-10, NCGC00014711-11, NCGC00014711-14, NCGC00014711-15, NCGC00094249-01, NCGC00094249-02, NCGC00094249-03, NCGC00094249-04, NCGC00094249-05, NCGC00094249-06, NCGC00094249-07, NCGC00261629-01, Oxaprozin 100 microg/mL in Acetonitrile, AC-26512, BO164184, NCI60_002681, SY050819, Oxaprozin Solution in Methanol, 100ug/mL, SBI-0050918.P002, 3-(4,5-Diphenyl-2-oxazolyl)propanoic acid, 3-(4,5-Diphenyloxazol-2-yl)propionic acid, AB00514024, EU-0100944, NS00008254, O0377, ST50949623, SW197319-4, 3-(4, 5-Diphenyl-2-oxazolyl)propenoic acid, EN300-25629, 3-(4,5-Diphenyl-oxazol-2-yl)-propionic acid, C07356, D00463, AB00514024_08, AB00514024_09, F066202, Q1749609, SR-01000076053-1, SR-01000076053-3, SR-01000076053-7, SR-01000076053-9, 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid #, BRD-K25394294-001-05-7, BRD-K25394294-001-08-1, BRD-K25394294-001-13-1, BRD-K25394294-001-14-9, Z212055564, Oxaprozin, United States Pharmacopeia (USP) Reference Standard, BJ6
Theoretical properties:
molecular_formula: C18H15NO3
molecular_weight: 293.3 g/mol
exact_mass: 293.10519334 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 4
rotatable_bond_count: 5
heavy_atom_count: 22
topological_polar_surface_area: 63.3 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: Crystals from methanol
color: Crystals from methanol
melting_point: 158-159 °C
solubility: Insoluble
Descriptions:
pubchem: Oxaprozin is a monocarboxylic acid that is a propionic acid derivative having a 4,5-diphenyl-1,3-oxazol-2-yl substituent at position 3. It is non-steroidal anti-inflammatory drug commonly used to relieve the pain and inflammatory responses associated with osteoarthritis and rheumatoid arthritis. It has a role as a non-steroidal anti-inflammatory drug and an analgesic. It is a monocarboxylic acid and a member of 1,3-oxazoles. It is functionally related to a propionic acid.
chebi: A monocarboxylic acid that is a propionic acid derivative having a 4,5-diphenyl-1,3-oxazol-2-yl substituent at position 3. It is  non-steroidal anti-inflammatory drug commonly used to relieve the pain and inflammatory responses associated with osteoarthritis and rheumatoid arthritis.
chembl: OXAPROZIN is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Oxaprozin, also known as oxaprozinum, is a nonsteroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. Chemically, it is a propionic acid derivative. Safety and efficacy has been established in children over 6 years with juvenile rheumatoid arthritis only, and there is an increased risk of adverse reactions in the elderly population.
It was patented in 1967 and approved for medical use in 1983.